The MORL is the only clinical lab in the United States associated with a state-of-the-art research center.  This unique collaboration allows the center to provide a complete range of complement genetic and complement-serological services, as well as expert clinical consultation and opportunities to participate in research for both providers and patients.  

Our Clinical Renal Diagnostics Division provides state-of-the-art next generation sequencing (NGS) of all genes that have been implicated in hereditary thrombotic microangiopathies (TMAs) and C3G: 

In addition to genetic testing, complement functional testing is integral to a complete evaluation of the complement system in patients with complement-mediated kidney diseases.  Defining the degree of complement activity in a given patient by testing complement activity and documenting where in the complement pathway dysregulation is the greatest by measuring complement biomarkers are instrumental in defining underlying disease characteristics.  This information in turn is useful for determining different aspects in clinical care (i.e. whether treatment may be discontinued or whether escalation of care should be considered).  Functional complement testing may also help in assessing the risk for relapse of complement-mediated kidney disease in the renal transplant setting. 

The MORL offers two large panels, the C3G Functional Panel and the TMA Functional Panel, to provide healthcare providers with an overview of their patient’s current complement activity.  Providers can then follow several abnormal findings with focused micro-panels or follow a single level to monitor clinical treatments.